Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2500 participants.

Also called NCT05712200

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,500 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05712200
  • EU CT 2023-503224-66-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Finland, Germany, Greece, Hungary, India, Israel, Italy, Japan, Latvia, Malaysia, Mexico, Peru, Philippines, Poland, Puerto Rico, Romania, Serbia, Slovakia, South Africa, South Korea, Spain, Sweden, Türkiye, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05712200. Randomized; double masking; primary purpose treatment. Start 2022-12-27 (actual); primary completion 2027-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Acronym
LILAC-TIMI 76
Condition
Atrial Fibrillation (AF)
Intervention (Biological)
Abelacimab
Intervention (Drug)
Placebo
Lead sponsor
Anthos Therapeutics, Inc. (class: industry)
Collaborator
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct05712200
Content hash
42fbfb3b83f59b330a753c574c3bf262b811c57a2e43200302971c1a28272769